Raymond James Financial
ITRM

Raymond James Financial’s Iterum Therapeutics ITRM Stock Holding History

Raymond James Financial’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,513
Closed -$4.49K – 5837
2025
Q2 		$4.49K Buy
+4,513
New +$4.71K ﹤0.01% 6198

Other funds holding ITRM

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Raymond James Financial's ITRM Position: Q3 2025 in Review

Raymond James Financial sold out of Iterum Therapeutics (ITRM) in Q3 2025, closing a stake of 4,513 shares — an estimated $4.49K sold.

Raymond James Financial first reported a position in ITRM in Q2 2025 and held it in 1 quarter. The position peaked at $4.49K in Q2 2025. 24 funds tracked by Wall St. Rank hold ITRM as of Q3 2025.

  • Raymond James Financial reported no remaining Iterum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 4,513 Iterum Therapeutics shares in Q3 2025, an estimated $4.49K.
  • Raymond James Financial first reported a position in Iterum Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Iterum Therapeutics position peaked at $4.49K in Q2 2025.
  • 24 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.